The price of heavy and large varieties is reduced by more than 50%

The collective "diving" price cuts of drugs

01 Price reduction of daratumomab injection

On July 27, the Hunan Provincial Public Resources Trading Center issued the "Publicity Regarding the Adjustment of the Online Prices of Certain Drugs

According to the document, the online prices of some drugs that relevant companies have applied for adjustments will be publicized, and the publicity period will be from July 27 to August 2, 2021

On the same day, the Centralized Procurement Network of Medicines and Medical Consumables in Liaoning Province issued the "Notice on the Implementation of the Results of Active Price Reduction of Two Drugs including Dalley Tuumab Injection

According to the notice, the Liaoning Provincial Public Resources Trading Center received an application from Xi’an Yangsen Pharmaceutical Co.

It is worth mentioning that in the list of price cuts, daratumomab injection once again appeared

Daratumumab is the first fully human monoclonal antibody targeting CD38 approved globally and domestically.

Financial report data shows that daratumomab's global sales in 2019 reached US$2.

The industry has speculated that the sharp price cut of daratumumab may pave the way for medical insurance

In addition, Henlius also received clinical approval from the National Food and Drug Administration on January 13 this year, agreeing to develop a recombinant anti-CD38 fully human monoclonal antibody injection (HLX15) to carry out clinical trials for the treatment of multiple myeloma

02 "Half-cut" prices pave the way for medical insurance

"For manufacturers, if you don't talk about it, it's a dead end.

In order to seek a larger market, the behavior of pharmaceutical companies to actively cut down the price of ace products may be traced back to 2019

Since then, news of a variety of anti-cancer drugs cut prices by more than 50% is not uncommon

Take tereprizumab as an example.

China's national medical insurance accounts for more than 95% of the overall medical insurance market, which has exerted considerable pressure on related drugs to reduce prices

According to the analysis of Industrial Securities, from the perspective of the products successfully negotiated in the previous medical insurance negotiations, the products with better competition pattern and the products with relatively fierce competition can achieve faster volume after being included in the medical insurance through negotiation, bringing flexibility to the corresponding products

It is foreseeable that it has gradually become the norm for innovative drugs to be included in the medical insurance negotiation catalogue at a significant price reduction in the early stages of the market
.
At the same time, the state has introduced a series of innovation benefits, such as accelerating the review and approval of innovative drugs, and patent extension policies to fully support the development of innovative drugs.
Innovation has become an unstoppable industry trend
.